Denosumab Treatment for Giant Cell Tumor of the Spine Including the Sacrum

Susan V Bukata, Jean-Yves Blay, Piotr Rutkowski, Keith Skubitz, Robert Henshaw, Leanne Seeger, Tian Dai, Danielle Jandial, Sant Chawla, Susan V Bukata, Jean-Yves Blay, Piotr Rutkowski, Keith Skubitz, Robert Henshaw, Leanne Seeger, Tian Dai, Danielle Jandial, Sant Chawla

Abstract

Study design: This was a subanalysis of an international, multicenter, open-label study.

Objective: The aim of this study was to assess the efficacy and safety of denosumab in a subset of patients with giant cell tumors of bone (GCTB) of the spine including the sacrum from an international, open-label, single-arm, phase 2 study (ClinicalTrials.gov: NCT00680992).

Summary of background data: Standard GCTB treatment is surgical removal, either by curettage or resection, combined with intraoperative adjuvant therapy; however, some sites may not be amenable to resection (e.g., skull, spine).

Methods: Adults or skeletally mature adolescents with pathologically confirmed GCTB of the spine including the sacrum, and radiologically measurable evidence of active disease, were included. Patients received denosumab (120 mg subcutaneously) once every 4 weeks during the treatment phase, with loading doses on days 8 and 15 of the first cycle. Patients had surgically unsalvageable GCTB (Cohort 1), had planned surgery expected to result in severe morbidity (Cohort 2), or were enrolled from a previous GCTB study (Cohort 3).

Results: Overall, 132 patients were included in the safety analysis (103 in Cohort 1, 24 in Cohort 2, and five in Cohort 3); 131 patients were included in the efficacy analysis. Kaplan-Meier estimated probabilities of disease progression or recurrence were 3% (95% confidence interval [CI], 0.0-6.2) at year 1 and 7.4% (95% CI, 2.1-12.7) at years 3 and 5 in Cohort 1, and not estimable in Cohorts 2 and 3. Of 23 patients (Cohort 2) with surgery planned at baseline, 10 (43%) had on-study surgery; of these, one patient had reported disease progression or recurrence after the on-study surgery. Clinical benefit was reported in 83% of patients overall (all cohorts).

Conclusion: Results from the analysis suggest that denosumab is potentially effective treatment for patients with GCTB of the spine including the sacrum. The adverse event profile was consistent with the full study population.Level of Evidence: 2.

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc.

Figures

Figure 1
Figure 1
Study design for administration of denosumab to patients with giant cell tumor of the bone. ∗Lead-in dosing for patients starting on denosumab. GCTB indicates giant cell tumor of bone; SC, subcutaneous.
Figure 2
Figure 2
Response to denosumab in spine (A) and sacrum (B). CT indicates computed tomography.

References

    1. Gamberi G, Serra M, Ragazzini P, et al. Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep 2003; 10:351–356.
    1. Rutkowski P, Ferrari S, Grimer RJ, et al. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol 2015; 22:2860–2868.
    1. Martin C, McCarthy EF. Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature. Iowa Orthop J 2010; 30:69–75.
    1. Turcotte RE. Giant cell tumor of bone. Orthop Clin North Am 2006; 37:35–51.
    1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Bone Cancer. Version 1.2020—August 12, 2019). Available at: . Accessed June 15, 2020.
    1. Sanjay BK, Sim FH, Unni KK, et al. Giant-cell tumours of the spine. J Bone Joint Surg Br 1993; 75:148–154.
    1. Khan DC, Malhotra S, Stevens RE, et al. Radiotherapy for the treatment of giant cell tumor of the spine: a report of six cases and review of the literature. Cancer Invest 1999; 17:110–113.
    1. Lin PP, Guzel VB, Moura MF, et al. Long-term follow-up of patients with giant cell tumor of the sacrum treated with selective arterial embolization. Cancer 2002; 95:1317–1325.
    1. Branstetter DG, Nelson SD, Manivel JC, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012; 18:4415–4424.
    1. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350:1655–1664.
    1. Skubitz KM, Cheng EY, Clohisy DR, et al. Gene expression in giant-cell tumors. J Lab Clin Med 2004; 144:193–200.
    1. Amgen XGEVA®. Denosumab. Thousand Oaks, CA: Amgen Inc; 2018.
    1. Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 2013; 14:901–908.
    1. Chawla S, Blay JY, Rutkowski P, et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol 2019; 20:1719–1729.
    1. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010; 11:275–280.
    1. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28:5132–5139.
    1. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377:813–822.
    1. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29:1125–1132.
    1. Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012; 48:3082–3092.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj